Similar articles

• Antibiotics at the crossroads.

  Nathan C. Nathan C. Nature. 2004 Oct 21;431(7011):899-902. doi: 10.1038/431899a. Nature. 2004. PMID: 15496893 No abstract available.
• But first, call your drug company: the doctor-patient relationship is being replaced by a drug marketer-patient bond.

  Weissman RX. Weissman RX. Am Demogr. 1998 Oct;20(10):27-30. Am Demogr. 1998. PMID: 10346668 No abstract available.
• Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions.

  Matter A, Keller TH. Matter A, et al. Drug Discov Today. 2008 Apr;13(7-8):347-52. doi: 10.1016/j.drudis.2008.02.005. Drug Discov Today. 2008. PMID: 18405848 Review.
• US drug industry bans expensive freebies for MDs, Canada raises fines.

  Sibbald B. Sibbald B. CMAJ. 2002 Sep 3;167(5):522. CMAJ. 2002. PMID: 12240824 Free PMC article. No abstract available.
• From health services to medical markets: the commodity transformation of medical production and the nonprofit sector.

  Imershein AW, Estes CL. Imershein AW, et al. Int J Health Serv. 1996;26(2):221-38. doi: 10.2190/V8XP-02T5-E44C-BHWG. Int J Health Serv. 1996. PMID: 9132373 Review.